Ardelyx enters commercial supply agreement with Catalent for IBSRELA through 2028

ARDELYX, INC.

Agreement covers tableting, testing, release and bulk packaging of IBSRELA (tenapanor HCl) at Catalent's Winchester, KY facility.
Initial term through Dec 31, 2028, with automatic renewal for two-year terms thereafter.
Minimum purchase commitment: minimum number of batches per contract year.
Unit pricing adjusted annually starting Jan 1, 2025, based on producer price index.
Either party can terminate for material breach after cure period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.